C. Pulicicchio

发表

Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625

T. Comery, K. Marquis, S. Grauer, 2011, Psychopharmacology.

Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK.

Michael A. Galella, K. McIntyre, J. Barrish, 2020, ACS medicinal chemistry letters.

The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists.

M. Day, T. Comery, S. Grauer, 2010, Journal of medicinal chemistry.

Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked

Michael A. Galella, K. McIntyre, J. Barrish, 2016, Journal of medicinal chemistry.

Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).

Michael A. Galella, K. McIntyre, J. Macor, 2019, Journal of medicinal chemistry.

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care

K. McIntyre, A. Fura, K. Gillooly, 2017, PloS one.

ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities

F. Liu, M. Day, T. Comery, 2008, Journal of Pharmacology and Experimental Therapeutics.

5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats.

Z. Hughes, G. Stack, S. J. Sukoff Rizzo, 2009, The international journal of neuropsychopharmacology.

An Electrophysiological Model of Spinal Transmission Deficits in Mouse Experimental Autoimmune Encephalomyelitis

J. Wettstein, E. Reilly, C. Pulicicchio, 2004, Journal of Pharmacology and Experimental Therapeutics.

WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent

F. Liu, M. Day, J. Dwyer, 2008, Neuropharmacology.

WAY‐318068: a novel, potent and selective noradrenaline re‐uptake inhibitor with activity in rodent models of pain and depression

P. Zhang, L. Leventhal, C. Beyer, 2010, British journal of pharmacology.

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D2 Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity

K. Marquis, S. Grauer, J. Brennan, 2010, Journal of Pharmacology and Experimental Therapeutics.

Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist

K. Marquis, S. Grauer, Radka Graf, 2010, Neuropharmacology.

Preclinical characterization of BRL 44408: antidepressant- and analgesic-like activity through selective alpha2A-adrenoceptor antagonism.

L. Leventhal, C. Beyer, J. Dwyer, 2010, The international journal of neuropsychopharmacology.

Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression

J. Brennan, J. Dwyer, R. Ring, 2013, Neuropharmacology.

Statistical Method for Analysis of the Disease Curve in Animals with Experimental Autoimmune Encephalomyelitis

Yonghee Lee, J. Wettstein, C. Pulicicchio, 2003, Journal of biopharmaceutical statistics.